<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621007</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-016</org_study_id>
    <nct_id>NCT03621007</nct_id>
  </id_info>
  <brief_title>An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes</brief_title>
  <acronym>NHS</acronym>
  <official_title>An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study. There are no protocol-defined visits, although patients are
      expected to have routine office visits approximately every 6 months. Upon signing of informed
      consent/assent and study enrollment, historical data will be abstracted from the patient's
      medical chart. The patient will then be observed prospectively for up to 5 years, with
      additional data collected from routine healthcare encounters and direct-to-patient
      questionnaires (where local laws allow), including laboratory tests, physical exam and
      patient reported outcomes/quality of life measures. Patients will be consented/assented to
      provide blood samples for biomarker assessments, DNA sequencing and archiving.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">August 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demographics</measure>
    <time_frame>Baseline</time_frame>
    <description>Descriptive summary of baseline characteristics including age, sex, ethnicity, and race.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical history</measure>
    <time_frame>5 years</time_frame>
    <description>Descriptive summary of medical history over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical course</measure>
    <time_frame>5 years</time_frame>
    <description>Descriptive summary of disease progression over time.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>POMC Deficiency Obesity</condition>
  <condition>PCSK1 Deficiency Obesity</condition>
  <condition>LEPR Deficiency Obesity</condition>
  <arm_group>
    <arm_group_label>POMC deficiency obesity</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>LEPR deficiency obesity</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PCSK1 deficiency obesity</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with POMC, PCSK1 or LEPR deficiency obesity due to a bi-allelic loss of function
        genetic mutation will be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 2 years or older

          2. Study participant and/or parent or guardian is able to communicate well with the
             investigator, to understand and comply with the requirements of the study, and be able
             to understand and sign the written informed consent/assent.

          3. Have documented results of DNA sequencing for the three genes of interest: POMC, PCSK1
             and LEPR.

          4. Bi-allelic, homozygous or compound heterozygous (a different gene mutation on each
             allele) genetic status for either the POMC or PCSK1 genes, resulting in a severe POMC
             deficiency obesity clinical phenotype, or a similar bi-allelic gene status for the
             LEPR gene leading to identified LEPR deficiency obesity.

        Exclusion Criteria:

          1. Participation within the past 3 months in a clinical trial of any investigational
             medicine for obesity.

          2. Having had a procedure intended to treat obesity in the past 3 months, including
             intensive diet and/or exercise regimen resulting in weight loss or weight
             stabilization or gastric bypass surgery that has resulted in &gt;10% weight loss.

          3. Confirmed diagnosis of Prader-Willi syndrome, Bardet-Biedl syndrome, Alström syndrome,
             or other syndromic form of genetic obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Stewart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siddhata Pandhare</last_name>
    <phone>8572644291</phone>
    <email>spandhare@rhythmtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Tip Fakultesi</name>
      <address>
        <city>Balçova</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Korcan Demir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University School of Medicine of Pediatric Endocrinology</name>
      <address>
        <city>Bornova</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebru Yilmaz</last_name>
      <phone>0090 534 013 18 74</phone>
    </contact>
    <investigator>
      <last_name>Samim Ozen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruhsar Damla Göksen Simsek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sukran Darcan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Endocrinology and Diabetes Marmara University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tülay Güran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMC</keyword>
  <keyword>LEPR</keyword>
  <keyword>PCSK1</keyword>
  <keyword>Bi-Allelic Loss</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

